Recombinant Human Collagen & Gelatin
FibroGen is the only producer of highly purified, fully characterized recombinant human (rh) collagens and gelatins intended to replace similar animal- or human-derived materials currently used in a variety of medical, pharmaceutical, and consumer applications. FibroGen has sold its products to over 100 institutions since introducing them to the market five years ago.
Recombinant Human Collagens and Gelatins: Development Programs
FibroGen welcomes the opportunity to discuss strategic alliances and co-development opportunities for its proprietary recombinant human collagens and gelatins. FibroGen is currently developing the following products:
| Product | Description | Application(s) |
|---|---|---|
| FG-5030 | rhCIII (cross-linked) | Cosmetic dermal filler |
| FG-5016 | rhCIII | Raw material for a variety of applications, e.g., tissue sealants/hemostats, drug delivery, wound healing, stents/vascular graft coatings, tissue engineering, cell attachment |
| FG-5009 | Low molecular weight (8.5 kDa), soluble rh Gelatin | Stabilizer for vaccines/biologics |
| Capsule | rh Gelatin | Capsules for oral drug delivery/food applications |
Reagent Store: Products Available for Research and In Vitro Evaluation
FibroGen produces recombinant human collagens and gelatins using in-house fermentation capacity. Select products intended for research and evaluation purposes are available for purchase through our Reagent Store (to visit FibroGen’s Reagent Store, please click here). Master Files are in preparation and will facilitate the incorporation of FibroGen biomaterials into customers' existing and future products. In the U.S., a Master File will be submitting to the appropriate Food and Drug Administration (FDA) reviewing center (e.g., CDRH, CDER, CBER) to provide detailed information related to the production of the product under review. Data will also be available for European and Japanese regulatory filings. Please contact customerservice@fibrogen.com for more information on research reagent purchases, clinical-grade materials, and contract pricing.
